Status:
ENROLLING_BY_INVITATION
A Pharmacist-Led Education Program to Improve Adherence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation
Lead Sponsor:
National Taiwan University
Conditions:
Atrial Fibrillation (AF)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Atrial fibrillation (irregular heartbeat) increases the risk of stroke, and patients are commonly treated with direct oral anticoagulants (DOACs). However, when patients do not take these medications ...
Eligibility Criteria
Inclusion
- 18 years of age or older
- have a confirmed diagnosis of AF
- are expected to begin DOAC therapy for at least 3 months for stroke prevention
Exclusion
- cannot understand DOAC-related education due to low literacy, language barriers, or cognitive impairment
- have been on DOAC therapy for more than 6 months
- using DOACs in off-label regimens
- are pregnant or breastfeeding
Key Trial Info
Start Date :
March 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2031
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT07159399
Start Date
March 5 2025
End Date
December 31 2031
Last Update
September 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan